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Abstract
Background: Adjuvant radiotherapy (RT) of regional lymph nodes (LN) in early breast cancer is still a matter of
debate. RT increases the Overall survival (OS) rate of breast cancer patients after breast conserving surgery and after
mastectomy in patients with involved LN. The contribution of RT to regional LN to this improvement was poorly
identified. Recently, the results of three large randomized trials addressing this question were published as full
papers.
Material and methods: Published data of the MA.20 (n = 1832), the EORTC22922–10925 (EORTC) (n = 4004) trial
and the French trial (n = 1334) were the foundation of this meta-analysis. Major eligibility criteria were positive i)
axillary LN (all trials), ii) LN negative disease with high risk for recurrence (MA.20), and iii) medial/central tumor
location (French, EORTC). The MA.20 and the EORTC trial analyzed the effect of additional regional RT to the internal
mammary (IM) LN and medial supraclavicular (MS) LN, whereas in the French trial all patients received RT to the
MS-LN and solely RT to the IM-LN was randomized. Primary endpoint was OS. Secondary endpoints were disease-
free survival (DFS) and distant metastasis free survival (DMFS).
Results: Regional RT of MS-LN and IM-LN (MA.20 and EORTC) resulted in a significant improvement of OS [Hazard
Ratio (HR) 0.88 (95 % CL 0.78 - 0.99)]. Adding results of the French trial and using a random effects model to
respect the different design of the French trial, the effect on OS of regional RT remained significant [HR 0.90 (95 %
CL 0.82 - 0.99)]. The absolute benefits in OS were 1 % in the MA.20 trial at 10 years, 1.6 % in the EORTC trial at
10 years, and 3.3 % in the French trial at 10 years (not significant in single trials). Regional RT of MS-LN and IM-LN
(MA.20 and EORTC) yielded to a significant improvement of DFS [HR 0.86 (95 % CL 0.78 - 0.95)] and DMFS [HR 0.84
(95 % CL 0.75 - 0.94)].
Conclusion: Additional regional RT to the internal mammary and medial supraclavicular LN statistically significantly
improved DFS, DMFS, and OS in stage I-III breast cancer.
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Introduction
Several clinical investigations showed that breast cancer
is a radiosensitive illness [1–6]. There are numerous data
which demonstrated that adjuvant RT after breast-
conserving surgery minimize the threat of ipsilateral in
breast relapse by at least a factor of 3 and halves the risk
of any disease recurrence resulting in a significantly im-
proved OS.
But there is still a dispute if regional LN should be
radiated in early breast cancer [7–9]. Therefore we
performed a meta-analysis to answer this question. In
our former meta-analysis we could show that additional
regional RT to the internal mammary and medial supra-
clavicular LN statistically significantly improved DFS,
DMFS, and OS in stage I-III breast cancer [7].
Meanwhile results of two randomized studies analyz-
ing these questions have recently been published as full
papers [10, 11]. Considering that our previous meta-
analysis and thus implications for management of breast
cancer therapy was solely based on abstracts of the two
studies, we were encouraged to carry out an update on
our published results.
Material and methods
We used the search term “breast cancer” and “RT” and
(“regional” or “nodal” or “internal mammary” or “para-
sternal” or “supraclavicular”) limited to “randomized
controlled trial” or “clinical trial, Phase III” in Pubmed
(August 2015) yielded 160 publications of possible inter-
est. In addition, we screened abstracts of important an-
nual cancer meetings including meetings of the
American Society of Clinical Oncology (ASCO), American
Society for Radiation Oncology (ASTRO), European
Cancer Congress (ECC), European Society for Radiation
Oncology (ESTRO), and San Antonio Breast Cancer
Meeting printed between January 2008 and September
2015. The quality of the available information was evalu-
ated according to the Cochrane guidelines. Especially,
assigned treatments needed to be done randomly, risk fac-
tors between treatment arm evenly distributed, exclusion
of patients from the analysis adequate, and analysis per-
formed on an intend to treat basis. Three trials met the
criteria to be included. Two papers were published simul-
taneously in the New England Journal of Medicine in
2015: the MA.20 [10] and the EORTC 22922–10925 trial
[12] and one paper from a French group was published in
the International Journal of Radiation Oncology Biology,
Physics in 2013 [13]. The patient characteristics from
these three randomized trials are available (Table 1). Two
publications analyzed the impact of additional IM-LN and
MS-LN RT and one investigation published the result of
additional RT of the IM-LN (Fig. 1). Information regard-
ing the radiation techniques used in the EORTC 22922–
10925 and the French trial [13] has been published. In the
MA.20 study, MC LN and level 3 axillary LN were treated
with an anterior filed. For RT of the IM-LN an adapted
wide tangent technique or a direct field corresponding to
tangent fields were applied. The inclusion criteria of the
studies were similar but not identical (Table 1). Most of
the patients had node positive status or medial/central tu-
mors. The primary end point of all trials was the OS rate.
Secondary endpoints were DFS, DMFS and loco regional
tumor control. Data on DFS and DMFS survival were
available solely in the MA.20 and the EORTC 22922–
Table 1 Patients characteristic
MA.20 [10] EORTC [12] French [13]
Recruitment years 2000 - 2007 1996 - 2004 1991 - 1997
Number of patients 1832 4004 1334
Median age 54 54 57
Node positive 90 % 56 % 75 %
Breast surgery 100 % breast conserving 76 % breast conserving 100 % mastectomy
CHX 91 % 55 % 61 %
ER/PR negative 32 % 40 % 7 %
Unknown ER/PR Status n.a. n.a. 40 %
Her-2neu n.a. n.a. n.a.
Main inclusion criteria N+ or high risk* N0 any location N+ or medial tumor N+ or medial/central tumor
Breast/chest wall Both arms: Both arms: Both arms: according to practice
of the center
50 Gy/25 fx 50 Gy/25 fx
Medial supraclavicular nodes Experimental arm: 45Gy/25 fx Experimental arm: 50 Gy/25 fx All patients: dose and fractionation
according to practice of the center
Internal mammary nodes Experimental arm: 45Gy/25 fx Experimental arm: 50 Gy/25 fx Experimental arm: 45 Gy/20 fx
*= > = 5 cm tumor, > = 2 cm tumor, and <10 axillary nodes removed with ER-, G3, or lymph vascular invasion; n.a. = not available; fx = fractions; ER = estrogene
receptor; PR = progesterone receptor
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10925, but not in the French investigation [13]. Since data
on regional tumor control was presented only in the
MA.20, this endpoint was not calculated in the meta-
analysis.
Statistical analysis
All investigations were stratified by trial. For analysis,
hazard ratios with 95 % confidence limits for OS, DFS,
and DMFS were extracted from the publications of the
MA.20 and the EORTC 22922–10925: Hazard ratio with
confidence limits for OS of the French trial was derived
from published survival curves according to the method
described by Parmar et al. [14], since no information on
hazard ratios were given in the publication. Taking into
account the detailed information on the patients at risk
during follow-up, this method is able to estimate the
hazard ratio quite accurately. Meta-analyses of the effect
sizes of the MA.20 and the EORTC 22922–10925 trials
on OS, DFS and DMFS were carried out using a fixed ef-
fect model based on parameter estimates of log hazard
ratios in Cox models and their standard errors. Since the
project of the French trial was slightly different from the
MA.20 and the EORTC 22922–10925 investigations, the
combined effect size for OS of all three trials were calcu-
lated based on a random effects model. Results are pre-
sented with forest plots, in which the estimates of the
hazard ratios of all single studies and their combined es-
timate are visualized. Horizontal bars show the amount
of variation (95 % confidence intervals of the parameter
estimates). All analyses were performed using MIX 2.0.
Results
A total of 7170 breast cancer patients from three ran-
domized trials were finally identified for this meta-
analysis. Patients’ characteristics in the different trials
are presented in Table 1. The regional RT (Fig. 2) of the
MS-LN and the IM-LN (MA.20 and EORTC 22922–
10925) study lead to a statistically significant improve-
ment of the OS rate in the combined analysis [Hazard
Ratio (HR) 0.88 (95 % CL 0.78 - 0.99), p = 0.034]. A
small, but statistically not significant, improvement in
OS was detected in the French trial, in which all patients
received MS-RT. In this trial solely the effect of
additional RT to IM-LN was tested (HR 0.94 (95 % CL
0.79 - 1.11), p = 0.80). Adding the results of the French
trial to the results of other trials (Fig. 2) and using a ran-
dom effects model to take into consideration that the
design of the French trial was not identical, the effect on
OS of regional RT remained statistically significant (HR
0.90 (95 % CL 0.82 - 0.99), p = 0.031). The absolute ben-
efits in OS were 1.6 % in the MA.20 trial at 5 years,
1.6 % in the EORTC 22922–10925 trial at 10 years, and
3.3 % in the French trial 10 years. The results for disease
free survival are shown in Fig. 3. LN irradiation leads to
a significant improvement when combining the results
for the MA.20 and EORTC studies containing n = 5836
patients [HR 0.86 (95 % CL 0.78 - 0.95), p = 0.003]. In
Fig. 4 the results for distant metastasis free survival are
shown. Here we could also find a significant improve-
ment for LN irradiation: n = 5836; HR 0.84 (95 % CL
0.75 – 0.94, p = 0.002). Figure 5 reflects the OS for the
subgroup analysis for the MA 20 and the EORTC trial.
A slight trend towards a larger improvement in OS from
regional RT was observer for patients with no lymph node
involvement compared to patients with lymph node in-
volvement. Acute and late side effects are illustrated in
Table 2. The absolute numbers for side effects are low in




Radiation fields in experimental arms
Fig. 1 Trial designs. Random= randomization. RT = RT. MS-LN-RT = RT of medial supraclavicular LN. MS-IM-RT = RT of medial supraclavicular and
internal mammary LN.
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Discussion
Patient recruitment periods in all studies span back for
more than ten years. The combined results of available
randomized trials showed a statistically significant im-
provement in OS for regional nodal RT in stage I-III
breast cancer patients (Fig. 2). The total OS benefit at
10 years was comparatively small (1.0 % to 3.3 %). How-
ever larger benefits were observed for disease free sur-
vival (MA.20: 5.0 %; EORTC: 3.0 %; Fig. 3) and distant
metastases free survival (MA.20: 3.9 %; EORTC: 4.0 %;
Fig. 4) indicating that a larger advantage may occur with
longer follow up. Locoregional tumor control at 10 years
was improved by 3.0 % in the MA.20 and by 1.2 % in the
EORTC trial. The respective data was not available from
the French trial. Possible mechanisms to explain, why
the effect of lymph node irradiation (LNI) on disease
free survival and distant metastases free survival is larger
than on locoregional tumor control were discussed pre-
viously [7]. In summary, an under-detection of recur-
rences in the IMC lymph nodes or immune stimulating
effects of LNI are possible explanations.
Unfortunately, with a few exceptions, the fact that dif-
ferent subgroups were analyzed in the 3 trials is making
the interpretation of the results and identification of
subgroups with larger benefits from LNI difficult. In
addition, the results of the few matching subgroups are
partially conflicting. According to the MA.20 trial, hor-
mone receptor negative patients have the largest survival
advantage from LNI, whereas hormone receptor positive
patients had no advantage. Subgroup analysis by hor-
mone receptor status is formally not available from the
EORTC trial. However, keeping in mind that almost all
Fig. 2 OS. Diamonds are proportional to weights used in meta-analysis, MS + IM =medial supraclavicular and internal mammary lymph node
irradiation, WBI/CWI = whole breast irradiation or chest wall irradiation, MS =medial supraclavicular lymph node irradiation.
Fig. 3 Disease free survivals. Diamonds are proportional to weights used in meta-analysis. MS + IM =medial supraclavicular and internal mammary
lymph node irradiation, WBI/CWI = whole breast irradiation or chest wall irradiation.
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patients in the MA.20 trial received chemotherapy, these
results are in obvious conflict to observation in the
EORTC trial indicating that patients, who had received
chemotherapy and endocrine therapy, which should be
those with hormone receptor positive tumors and add-
itional high risk features and insofar correspond well to
the hormone receptor positive patients in the MA.20
trial, had a large benefit from LNI. To resolve this con-
flict, joint subgroup analyses of both trials should be ini-
tiated and would probably helpful to implement these
important results into clinical practice.
Subgroup analyses by lymph node involvement were
available from all trials, but sufficient data for a formal
meta-analysis available only from the MA.20 and
EORTC trial. Patients without involved lymph nodes
seem to have a larger advantage from LNI than patient
with more than 3 involved lymph nodes (Fig. 5). In the
fresh trial, patients with 1–3 involved lymph nodes had
a larger survival advantage than pN0 patients. In the
MA.20 and the EORTC trial, patients, who underwent a
complete axillary dissection (>10 nodes), had consist-
ently a larger benefit from LNI than patients with in-
complete axillary dissection. Results according to tumor
location (lateral versus central/medial) were inconsistent
between trials. Neither data on tumor size nor on tumor
grade was available form more than one trial. Overall,
Fig. 4 Distant metastases free survival. Diamonds are proportional to weights used in meta-analysis. MS + IM =medial supraclavicular and internal
mammary lymph node irradiation, WBI/CWI = whole breast irradiation or chest wall irradiation.
Fig. 5 OS for the subgroup analysis. Diamonds are proportional to weights used in meta-analysis
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there is the impression, but no proof, that patients with
higher risk tumors with no or limited lymph node in-
volvement benefit most from LNI.
AntiHer2 therapy was not established at the time,
when these trials were initiated.Correspondingly, no in-
formation on the Her2-status of the patients is available
and trastuzumab was not given to any patient during
primary treatment. Accordingly, one can only speculate
on the impact of an anti-Her2-therapy on the effect of
LNI. Interestingly, a retrospective analysis of the Her2
status of the Danish DBCG 82 b and c trials [15] showed
that RT (chest wall + LN) after mastectomy results in no
improvement of overall survival in Her2 positive breast
cancer, but in a 10 % overall survival gain in hormone
receptor positive cancer. This observation indirectly im-
plies that the observed survival benefit from LNI re-
ported here, does not originate from Her2 positive
cancer and thus would not be expected to disappear by
adding anti-Her2 therapies.
Systemic chemotherapy in the trials on LNI was
administered according to the standard treatments at
the time of patient’s recruitment (French: 1991–1997.
EORTC: 1996–2004, MA.20: 2000–2007). Accordingly,
only a few patients in the French trial received anthracy-
clines and the majority CMF. Although no information
is available on the type of chemotherapy in the EORTC
trial, one can assume that anthracycline containing regi-
mens were frequently used and in a smaller part of pa-
tients taxenes were given. Anthracycline containing
chemotherapy was administered in the MA.20 and in
approximately in 50 % of those receiving chemotherapy,
in addition a taxane was given. Compared to current
standards, chemotherapies in the French and in part also
in the EORTC trial have to be considered outdated,
whereas the chemotherapy in the MA.20 trials could still
be regarded as acceptable. The effects of LNI were quite
similar between trials indirectly indicating that the effect
of LNI may not be substantially changed by more effect-
ive chemotherapies. New trials would be necessary for a
scientific prove. Since at least 10 year follow up is re-
quired in breast cancer to see effects of radiotherapy on
overall survival, systemic treatments would likely consid-
ered outdated again at the time of publication of such
trials. As long as systemic treatments evolve rapidly,
physicians have to cope with the fact that indications for
radiotherapy are based on trials that did not use the
Table 2 Acute and late side effects during radiation therapy
Ma 20 [10] EORTC [12] French [13]
MS-IM- IM-IM+ p MS-IM- IM-IM+ p MS-IM- IM-IM+ p
Acute side effects
Fatique grade 2/3 18.2 % 19 % n.s. n.a. n.a. n.a. n.a. n.a. n.a.
Pain 4.3 % 5.9 % n.s. n.a. n.a. n.a. n.a. n.a. n.a.
Radiation dermatitis grade 2/3 40.1 % 49.5 % <0.001 n.a. n.a. n.a. n.a. n.a. n.a.
Lung
Acute side effect (pneumonitis) grade 2 0.2 % 1.2 % 0.01 n.a. n.a. n.a. n.a. n.a. n.a.
Acute side effect (pneumonitis) grade 3 0 % 0 % n.s. n.a. n.a. n.a. n.a. n.a. n.a.
Acute side effect (pneumonitis) grade 4 0 % 0 % n.s. n.a. n.a. n.a. n.a. n.a. n.a.
Late side effect (fibrosis) grade 2/3 0.3 % 0.4 % n.s. n.a. n.a. n.a. n.a. n.a. n.a.
Late side effect (fibrosis) grade 4 0 % 0 % n.s. n.a. n.a. n.a. n.a. n.a. n.a.
Late side effect any grade n.a. n.a. n.a. 1.7 % 4.4 % <0.0001 n.a. n.a. n.a.
Lymphedemia (arm)
Grade 2/3 4.5 % 8.4 % 0.001 n.a. n.a. n.a. n.a. n.a. n.a.
Grade 4 0 % 0 % n.s. n.a. n.a. n.a. n.a. n.a. n.a.
Any grade n.a. n.a. n.a. 3.6 % 3.8 % n.s. n.a. n.a. n.a.
Cardiac (any grade)
Cardiac fibrosis n.a. n.a. n.a. 0.6 % 1.2 % n.s. 1.7 % 2.2 % n.s.
Cardiac disease n.a. n.a. n.a. 5.6 % 6.5 % n.s. n.a. n.a. n.a.
Other cardiac side effects grade 2/3 0.4 % 0.9 % n.s. n.a. n.a. n.a. n.a. n.a. n.a.
Second cancers (n) n.a. n.a. n.a. 222 191 n.a. n.a. n.a. n.a.
Total late side effects
Any grade n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
> grade 2 n.a. n.a. n.a. n.a. n.a. n.a. 2.3 % 3.1.% n.s.
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latest standard of systemic treatment. This should not
result in an underuse of radiotherapy.
The small benefit of LNI has to be assessed against the
additional toxicity. Importantly, no grade IV toxicities
were reported. However, LNI is associated with signifi-
cantly more grade II-III acute skin toxicity and grade I-II
lung (Table 2). Grade III lung toxicity was rare (<0.5 %)
and not more frequent after LNI. Grade II-III lymph-
edema was significantly increased after LNI (8.4 % versus
4.5 %) in the MA.20 trials, but not in the EORTC trial.
The on average larger radiation fields to the axilla used
in the MA.20 trial (Fig. 1) could serve as a plausible ex-
planation for this difference. The fear that radiotherapy
to the IMC LN would result in substantially higher car-
diac toxicity was not confirmed after already at 10 years
follow-up.
One weakness of this meta-analysis is that it is not
based on the data of the individual patients, precluding
some important subgroup analyses.
In summary, LNI results in a moderate, but statisti-
cally significant improvement in disease free survival,
distant metastases free survival and overall survival with-
out adding substantial toxicity. Subgroup analyses form
published data remain inconclusive, which patients
benefit most from LNI.
Based on the available data, it is not easy to give un-
ambiguous recommendations for the implementation of
LNI to clinical practice. We think LNI can be advised to
patients at higher risk of recurrence, who received
systemic chemotherapy in two clinical situations: 1.
pN1-pN2 lymph node involvement regardless the tumor
location, and 2. pN0 in centrally of medially located tu-
mors. Patients with Her-2 positive tumors, who are
treated with trastuzumab and patients with relevant car-
diac risk factors should receive supra/infraclavicular
lymph node radiation only, but no radiotherapy the in-
ternal mammary lymph nodes. Risks and benefits should
be discussed in detail.
Conclusion
Additional regional RT to the internal mammary and
medial supraclavicular LN statistically significantly im-
proves DFS, DMFS, and OS in stage I-III breast cancer
patients.
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